Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 8/20 | 0.51 |
| ▸ | NAMPT | P43490 | 2/20 | 0.47 |
| ▸ | SIRT3 | Q9NTG7 | 7/20 | 0.46 |
| ▸ | SIRT1 | Q96EB6 | 6/20 | 0.46 |
| ▸ | SYK | P43405 | 1/20 | 0.46 |
| ▸ | AURKA | O14965 | 2/20 | 0.46 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.46 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.45 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.41 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.41 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6079858 | 0.81 | SYK (0.45) | NAMPTSYKCYP17A1 | |
| SCHEMBL18213795 | 0.78 | SIRT2 (0.52) | SIRT2NAMPTSYKAURKARPS6KB1 | |
| SCHEMBL14305094 | 0.78 | SIRT2 (0.52) | SIRT2SYKAURKARPS6KB1CYP17A1 | |
| SCHEMBL6079543 | 0.78 | KMT2A (0.49) | SIRT2SIRT3SIRT1 | |
| SCHEMBL26326355 | 0.78 | SIRT2 (0.51) | SIRT2SIRT3SIRT1SYKAURKA | |
| SCHEMBL2675781 | 0.77 | AURKA (0.49) | SIRT2NAMPTAURKARPS6KB1CYP17A1 | |
| SCHEMBL18347092 | 0.77 | SIRT2 (0.76) | SIRT2SIRT3SIRT1 | |
| SCHEMBL6227683 | 0.76 | SIRT2 (0.42) | SIRT2SIRT3SIRT1 | |
| SCHEMBL27498370 | 0.76 | CYP3A4 (0.50) | SIRT2NAMPTSYKAURKARPS6KB1 | |
| SCHEMBL31139283 | 0.75 | SIRT2 (0.50) | SIRT2NAMPTSYKAURKARPS6KB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060063782-A1 | 3-Hetero arylmethoxy ! pyridines and their analogues as p38 map kinase inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2006-03-23 | — | — | US | disclosed |
| EP-1545523-A1 | 3-&-grave;(HETERO) ARYLMETHOXY ! PYRIDINES AND THEIR ANALOGUES ASP38 MAP KINASE INHIBITORS | Astex Technology Limited (GB) | 2005-06-29 | — | — | EP | disclosed |
| WO-2005002673-A1 | RAF KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2005-01-13 | — | — | WO | disclosed |
| WO-2004004720-A1 | 3-`(HETERO) ARYLMETHOXY ! PYRIDINES AND THEIR ANALOGUES AS P38 MAP KINASE INHIBITORS | ASTEX TECHNOLOGY LIMITED (GB) | 2004-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063782-A1 | 3-Hetero arylmethoxy ! pyridines and their analogues as p38 map kinase inhibitors | MAPK1, MAPK3, MAPK10 | SIRT2 1669/4885NAMPT 1734/4885SIRT3 1402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.